

1AP20 Reg'd Patent 01 MAR 2006

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 2	Application Number	Unassigned
	Filing Date	March 1, 2006
	First Named Inventor	Koenraad Lodewijk August Van Acker 1045510358
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	TIP-0062-USPCT

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
/NK/		EP	1 335 019	A1	Takeda Chemical Industries, Ltd.	08-13-2003		

Examiner Signature	/Nicole Kinsey/	Date Considered	09/25/2007
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

1AP20 Rec'd MPTO 01 MAR 2006

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2	Application Number	Unassigned
	Filing Date	March 11, 2006
	First Named Inventor	Koenraad Lodewijk August Van Acker
	Group Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	TIP-0062-USPCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
/NK/		Fenard et al., "Secreted phospholipases A ₂ , a new class of HIV inhibitors that block virus entry into host cells", Journal of Clinical Investigation, vol. 104, no. 5, pp. 611-618 (1999).	
		Ojwang et al., "T30177, an Oligonucleotide Stabilized by an Intramolecular Guanosine Octet, Is a Potent Inhibitor of Laboratory Strains and Clinical Isolates of Human Immunodeficiency Virus Type 1", Antimicrobial Agents and Chemotherapy, vol. 39, no. 11, pp. 2426-2435 (1995).	
		Nakashima et al., "Anti-Human Immunodeficiency Virus Activity of a Novel Synthetic Peptide, T22 ([Tyr-5,12, Lys-7]Polyphemusin II): a Possible Inhibitor of Virus-Cell Fusion", Antimicrobial Agents and Chemotherapy, vol. 36, no. 6, pp. 1249-1255 (1992).	
		Pannecouque et al., "New Class of HIV Integrase Inhibitors that Block Viral Replication in Cell Culture", Current Biology, vol. 12, no. 14, pp. 1169-1177 (2002).	
		Lin et al., "A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding", Proceedings of the National Academy Sciences of the USA, vol. 100, no. 19, pp. 11013-11018 (2003).	
		Pauwels et al., "Potent and selective inhibition of HIV-1 replication <i>in vitro</i> by a novel series of TIBO derivatives", Nature, vol. 343, no. 6257, pp. 470-474 (1990).	
		Spenlehauer et al., "A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assay That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type 1", Virology, vol. 280, no. 2, pp. 292-300 (2001).	
		Richman et al., "An adenovirus-based fluorescent reporter vector to identify and isolate HIV-infected cells", Journal of Virological Methods, vol. 99, nos. 1-2, pp. 9-21 (2002).	
		Lee et al., "Generation of the Replication-Competent Human Immunodeficiency Virus Type 1 Which Expresses a Jellyfish Green Fluorescent Protein", Biochemical and Biophysical Research Communications, vol. 233, no. 1, pp. 288-292 (1997).	
↓		Internet Article, "Online!", "Staccato Cell Station™ - Assay", February 2003, pp. 1-2 (XP002271113).	
/NK/		Internet Article "Online!", "Automation of Cell-Based Assays", April 2003, pp. 1-4 (XP002271114).	

Examiner Signature	/Nicole Kinsey/	Date Considered	09/25/2007
---------------------------	-----------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1AP20 Rec'd at CPTO 01 MAR 2006

SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	Unassigned
Filing Date	March 1, 2006
First Named Inventor	Koenraad Lodewijk August Van Acker
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	TIP-0062-USPCT

8

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature	/Nicole Kinsey/	Date Considered	09/25/2007
-----------------------	-----------------	--------------------	------------